HedgePath welcomes strong PhII oral carcinoma results

An article by FiercePharma
August 9, 2016

Florida’s HedgePath Pharmaceuticals heralded a positive midstage study for its oral capsules designed to treat a complication associated with basal cell carcinoma. The oral regimen demonstrated effectiveness in reducing tumor size, delaying or eliminating the need for surgery.

Basal cell carcinoma nevus syndrome (BCCNS) is the result of a genetic mutation that causes a major regulatory process to malfunction. This process, the Hedgehog pathway, controls cell development in healthy embryos, but in patients with the disease, it causes disfiguring lesions on the face.

Normally, BCCNS would require surgery. But the capsule SUBA-itraconazole gives patients the option to control the symptoms of the disease without an invasive removal, which can cause massive scarring. The FDA orphan drug-designated antifungal candidate is a formulation with improved bioavailability to be administered orally.


Read more here